CRISPR Therapeutics (NASDAQ:CRSP) Trading 0% Higher

CRISPR Therapeutics AG (NASDAQ:CRSP) rose 0% during mid-day trading on Monday . The stock traded as high as $57.16 and last traded at $55.90. Approximately 465,373 shares were traded during mid-day trading, a decline of 74% from the average daily volume of 1,756,152 shares. The stock had previously closed at $55.89.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Wells Fargo & Company boosted their price target on CRISPR Therapeutics from $55.00 to $70.00 and gave the company an “equal weight” rating in a research note on Thursday, February 22nd. Citigroup lifted their price objective on shares of CRISPR Therapeutics from $88.00 to $89.00 and gave the company a “buy” rating in a research note on Thursday, April 18th. Royal Bank of Canada raised their target price on shares of CRISPR Therapeutics from $57.00 to $66.00 and gave the stock a “sector perform” rating in a report on Thursday, February 22nd. Needham & Company LLC reaffirmed a “buy” rating and issued a $90.00 price target on shares of CRISPR Therapeutics in a report on Thursday, April 11th. Finally, Wolfe Research assumed coverage on CRISPR Therapeutics in a report on Thursday, February 15th. They issued a “peer perform” rating for the company. Three analysts have rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $76.29.

CRISPR Therapeutics Stock Down 4.0 %

The firm has a market cap of $4.52 billion, a price-to-earnings ratio of -27.45 and a beta of 1.80. The company’s 50-day moving average price is $66.49 and its 200-day moving average price is $64.72.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Wednesday, February 21st. The company reported $1.10 EPS for the quarter, topping the consensus estimate of $0.15 by $0.95. The firm had revenue of $201.20 million for the quarter, compared to analysts’ expectations of $148.72 million. CRISPR Therapeutics’s quarterly revenue was up 3253.3% on a year-over-year basis. During the same quarter last year, the firm posted ($1.41) earnings per share. Analysts predict that CRISPR Therapeutics AG will post -6.24 earnings per share for the current fiscal year.

Insider Buying and Selling at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 20,000 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $80.36, for a total value of $1,607,200.00. Following the completion of the sale, the chief executive officer now directly owns 187,377 shares in the company, valued at $15,057,615.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, CEO Samarth Kulkarni sold 20,000 shares of the stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $80.36, for a total value of $1,607,200.00. Following the completion of the sale, the chief executive officer now owns 187,377 shares of the company’s stock, valued at $15,057,615.72. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, General Counsel James R. Kasinger sold 2,801 shares of the business’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $78.26, for a total value of $219,206.26. Following the transaction, the general counsel now directly owns 60,070 shares in the company, valued at approximately $4,701,078.20. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 83,992 shares of company stock worth $6,132,335. Corporate insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On CRISPR Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of CRSP. Jump Financial LLC raised its position in shares of CRISPR Therapeutics by 194.7% during the 3rd quarter. Jump Financial LLC now owns 33,307 shares of the company’s stock valued at $1,512,000 after buying an additional 22,006 shares during the period. Invesco Ltd. lifted its stake in shares of CRISPR Therapeutics by 1.5% in the 3rd quarter. Invesco Ltd. now owns 136,123 shares of the company’s stock valued at $6,179,000 after purchasing an additional 2,061 shares during the last quarter. ARK Investment Management LLC grew its holdings in shares of CRISPR Therapeutics by 19.2% during the 4th quarter. ARK Investment Management LLC now owns 8,536,104 shares of the company’s stock worth $534,360,000 after purchasing an additional 1,372,986 shares during the period. Prime Capital Investment Advisors LLC acquired a new stake in shares of CRISPR Therapeutics during the 4th quarter worth about $206,000. Finally, Baker Chad R raised its holdings in CRISPR Therapeutics by 89.1% in the 4th quarter. Baker Chad R now owns 98,520 shares of the company’s stock valued at $6,167,000 after buying an additional 46,420 shares during the period. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.